Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CNDO AUTISM DATA --DR. ERIC HOLLANDER is a world renowned AUTISM physician at Montefiore & Einstein----very impressive imo.
I know I'm ready to get back to 12.
CNDO SOARING TO $12? ---CNDO selling AT CASH, and with GOOD AUTISM NEWS---SKYROCKET tomorrow imo.
Congrats CNDO holders!!! WooHoo, nice afterhours action today. Great NEWS. Should set up for a nice climb going forward.
Go CNDO
Hey I'm late to the game but interested in learning about the company. I have a brother-in law that suffers from a form of autism(aspergers).
What phase trial do these early results refer to today? TIA
CNDO---DR. HOLLANDER reports favorable AUTISM NEWS for 3 measures of the disease---DR. HOLLANDER is the DIRECTOR of AUTISM SPECTRUM DISORDER PROGRAM at the Montefiore Medical Center and the EINSTEIN COLLEGE OF MEDICINE !
yeah not worried about lil pullbacks. This is heavy AH volume. 675k+... nice. It's not like the run is on 50k shares or something. I'm loving this. haha
CNDO --AUTISM STATISTICALLY SIGNIFICANT SEPARATION FROM PLACEBO for 3 measures of the disease -----DR. HOLLANDER, a well regarded AUTISM EXPERT----FINALLY SOME GOOD NEWS for AUTISM PATIENTS.
$2.30 hit
$2.24 hit. It's in the gap babyyy
I like it, let's keep this going
$2.08 300k+ volume... nice
Coronado Biosciences Announces Presentation of Interim Data From Autism Study at Neuropsychopharmacology Meeting
GlobeNewswire Coronado Biosciences, Inc.
4 minutes ago
Study Investigator Eric Hollander, M.D., Reports Potential Benefits of TSO Immunotherapy in First 5 Patients
Study Completion and Final Results Expected Mid-2014
BURLINGTON, Mass., Dec. 12, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (CNDO), a biopharmaceutical company developing novel immunotherapy agents for the treatment of autoimmune diseases and cancer, today announced that Dr. Eric Hollander, Clinical Professor of Psychiatry and Behavioral Sciences at Albert Einstein College of Medicine of Yeshiva University and Director of the Autism and Obsessive Compulsive Spectrum Program at Montefiore Medical Center and Einstein, presented interim data from his pilot study of oral TSO (Trichuris suis ova or CNDO-201) to treat autism at the American College of Neuropsychopharmacology Annual Meeting in Hollywood, Florida.
The study is a double-blind, randomized, placebo-controlled, cross-over study and enrolled 10 high-functioning adult autism spectrum disorder patients who were able to give informed consent to participate in the study and who had a history of allergies and/or a family history of immune-inflammatory illness. They were treated for 12 weeks with either TSO or placebo, followed by a 4-week washout phase and then 12 weeks of placebo or TSO. The TSO dosage used in the study was 2,500 ova once every two weeks.
In the first 5 patients that completed the study, there was a statistically significant separation from placebo in favor of TSO on three measures of disease: the Montefiore-Einstein Rigidity Scale (MERS), the Repetitive Behavior Scale-Revised (RBS-R) Sameness Scale, and the Social Responsiveness Scale (SRS)-Repetitive Behaviors Scale. The treatment was well tolerated.
The study is still ongoing and final results are expected in the middle of 2014.
"There is increasing evidence that immune dysregulation plays an important role in this developmental disorder and we are encouraged by the interim data from this pilot study with TSO," said Dr. Harlan F. Weisman, Coronado's Chairman and CEO. "We believe autism is an area of unmet medical need where a natural immune system regulator like TSO may help a part of the autism population."
This is about as irritating as it gets
yeah,giving it all right back. What a shame.
What a negative turn, pump and dump?
I'm ready for 4 to get back here
Charts look like they have plently of room to run now.
Go CNDO
8:12AM Coronado Biosciences announces IND submission for TSO for the Treatment of Moderate to Severe Chronic Plaque Psoriasis (CNDO) 1.72 : Co announced that it has submitted an Investigational New Drug application to the U.S. Food and Drug Administration to begin a Phase 2 clinical study of Trichuris suis ova (TSO) for the treatment of moderate to severe chronic plaque psoriasis.
"We believe psoriasis represents a medical need where a natural immune system regulator like TSO may provide considerable sustained relief to those with the condition," said Dr. Harlan F. Weisman, Coronado's Chairman and CEO. "Psoriasis is a logical human clinical model for immune-mediated diseases because clear, validated and objective endpoints can be established and there are low placebo rates. As such, we believe it is a good disease model in which to determine the potential immunomodulatory effect of TSO."
Coronado is also pursuing the trial based upon encouraging preliminary results from open-label investigator-sponsored trials at two U.S. centers that are currently evaluating multiple doses of TSO in patients with psoriasis. Coronado's proposed Phase 2 trial is a U.S. multi-center, dose-ranging study that will use the Psoriasis Area and Severity Index score from week 0 to week 12 to assess efficacy. Coronado intends to begin enrolling patients in the trial during Q1 of 2014 if the IND application is approved.
nice news CNDO
CNDO News. Looking good in the PM.
Coronado Biosciences Announces IND Submission for TSO for the Treatment of Moderate to Severe Chronic Plaque Psoriasis
8:00a ET December 9, 2013 (GlobeNewswire)
Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of autoimmune diseases and cancer, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration to begin a Phase 2 clinical study of Trichuris suis ova (TSO) for the treatment of moderate to severe chronic plaque psoriasis.
"We believe psoriasis represents a medical need where a natural immune system regulator like TSO may provide considerable sustained relief to those with the condition," said Dr. Harlan F. Weisman, Coronado's Chairman and CEO. "Psoriasis is a logical human clinical model for immune-mediated diseases because clear, validated and objective endpoints can be established and there are low placebo rates. As such, we believe it is a good disease model in which to determine the potential immunomodulatory effect of TSO." Coronado is also pursuing the trial based upon encouraging preliminary results from open-label investigator-sponsored trials at two U.S. centers that are currently evaluating multiple doses of TSO in patients with psoriasis.
Coronado's proposed Phase 2 trial is a U.S. multi-center, dose-ranging study that will use the Psoriasis Area and Severity Index score from week 0 to week 12 to assess efficacy. Coronado intends to begin enrolling patients in the trial during the first quarter of 2014 if the IND application is approved.
About Psoriasis
Psoriasis (psoriasis vulgaris) is a chronic inflammatory skin disease characterized by red, scaly, raised plaques. The disease process is driven by T-cell infiltration and associated elevation in cytokine levels leading to increased cell division and aberrant differentiation, resulting in the psoriatic phenotype. Plaque psoriasis has a worldwide prevalence of 2-3%, and is a chronic, recurrent skin condition with varying degrees of severity. While many patients with mild disease are able to control psoriasis symptoms with topical medications alone, patients with moderate to severe disease usually require treatment with systemic agents to achieve good clearance. These systemic agents are usually well tolerated, but can have potentially significant side effects including organ toxicity, infection, malignancy, and teratogenicity that limit their usefulness in the long-term management of psoriasis. Despite all the available treatments, there is still a need for therapies that will provide high continuous efficacy, improved safety, and a more convenient route of administration to maximize compliance and satisfaction with treatment, leading to decreased burden of the disease.
About Coronado Biosciences
Coronado Biosciences is engaged in the development of novel immunotherapy biologic agents. The company's two principal pharmaceutical product candidates in clinical development are: TSO (Trichuris suis ova or CNDO-201), a biologic for the treatment of immune-mediated diseases, such as psoriasis, Crohn's disease, ulcerative colitis and multiple sclerosis; and CNDO-109, a biologic that activates natural killer cells, for the treatment of acute myeloid leukemia, multiple myeloma and solid tumors. For more information, please visit www.coronadobiosciences.com.
Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks relating to the results of research and development activities; our ability to attract, integrate and retain key personnel; uncertainties relating to preclinical and clinical testing; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; our dependence on third party suppliers; and competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
CONTACT: Lucy Lu, MD, Executive Vice President
& Chief Financial Officer
Coronado Biosciences, Inc.
781-652-4525; ir@coronadobio.com
http://www.globenewswire.com/newsroom/ti?nf=MTMjMTAwNjA3NTcjMjg4ODk=
$1.60 holding again today. Might be a good spot to add. Still haven't and missed out on the low a few weeks ago
It's held a couple days. Let's hope this heads north soon!
Sure is turning out to be a nice Thanksgiving as long as this keeps up.
$1.6 hit today! 28% big bounce so far from the bottom price $1.25!
When that happens one will end up chasing at the multiple dollars...
A pipe dream to hit $1! $1.25 will be the forever bottom price!
You missed the huge opportunity to make easy 20% quick gain by waiting for a impossible price! How did you get the price target anyway? I told all $1.27 should be the bottom! However the MMs manipulated the price down to $1.25 which is just two cents below...
Big surprise today! $1.44 held the support for the whole day! So it should test yesterday's high $1.54 again tomorrow...
The impatient sellers took the price down to $1.44 now! Hopefully it won't crash to $1.25 again or even hit the new low $1.23 like it did from $1.27 to $1.25 before... Too many MM's and Analyst's manipulations to this mostly undervalued bio-tech gem!
Opened with 19.5k @ $1.52
LOL! Someone dumped 19,200 shares at $1.3782 and 800 shares at $1.4587 in the AH session!
IMO, $1.25 will be the forever bottom price unless the bankruptcy filing which is impossible in the near future!
Followers
|
19
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
465
|
Created
|
02/14/12
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |